VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...
/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023.
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022.
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss...
Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.
Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.
USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French...